Shionogi Company Limited

Astrazeneca Ab

Astra Zeneca U.k. Limited

Tetsuo Okada

Hideyuki Takenaka

Kohji Hanasaki

Masahiro Fuji

Yasuyuki Kawanishi

Makoto Kakinuma

Mitsuaki Ohtani

Masayuki Narisada

Teruji Tsuji

Makoto Adachi

Nigel Philip Taylor

Tomoyuki Ogawa

Yoshio Hamashima

Fumihiko Watanabe

Tsunetoshi Honma

Hiromu Matsumura

Yoshiharu Hiramatsu

Koji Ishikura

Kyoji Minami

Tadahiko Tsushima

John Horbury

Hisao Sato

David Dermot Patrick Laffan

Hiroyuki Ishitobi

A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.

Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof

The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound or the formula (I): 

NPY Y5 antagonist

The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein Ris lower alkyl, cycloalkyl or the like,

The invention relates to crystalline salts of the compound (E)-7-[4-(4-fluorophenyl)isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid of formula (I), as well as processes for their manufacture, pharmaceutical compositions containing them, and their uses 

Crystalline salts of 7-'4-(4-fluorophenyl) -6-isopropyl-2-&#x2032;methyl (methylsulfonyl) amino!pyrimidin-5-yl!- (3R, 5S) -3, 5-dihydroxyhept-6-enoic acid

The invention relates to crystalline salts of the compound (E)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl(methyl-sulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid of formula (I), as well as processes for their manufacture, pharmaceutical compositions containing them, and their uses

Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid

Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities

Npyy5 antagonists

Tricyclic compounds having sPLA2-inhibitory activities

A process for preparing a compound having PGD antagonism represented by the formula (I), or a pharmaceutically acceptable salt or hydrate thereof, which process comprises reacting an amino alcohol of the formula (II) or its salt with a compound of the formula (III) or its reactive derivative, oxidizing the product with halo oxoacid in the presence of 2,2,6,6-tetramethylpiperidine-1-oxyls, reacting the product with an ylide under the conditions for Wittig reaction, and optionally deprotecting the product.

Process for preparing benzothiophenecarboxamide derivatives

Pyrrolo&lsqb;1,2-a&rsqb;pyrazine spla2 inhibitor

Process for producing benzothiophenecarboxylic acid amide derivatives

The present invention relates to process for the isolation of (-)-(S)-3-methylamino-4-methylenepyrrolidine derivatives of the formula: ##STR1## wherein R is hydrogen or amino-protecting group, from the racemic mixture of them comprising the salt formation of the racemate with L-(+)-tartaric acid in a molar ratio of 2:1 and subsequent treatment with a base, and optionally followed by deprotection of the amino-protecting group. By this process, complicated procedure in resolutional crystallization is not necessary and (-)-(S)-3-methylamino-4-methylenepyrrolidine derivatives can be obtained as optically pure form in above 90% yield quantitatively by single procedure.

Optically active cyclic amine and the process of optical resolution

Novel quinolonecarboxylic acids of the formula: ##STR1## wherein R.sup.1 is C.sub.1 -C.sub.4 alkyl, R.sup.2 and R.sup.3 each is identically or differently hydrogen or C.sub.1 -C.sub.4 alkyl, R.sup.4 is cyclopropyl, phenyl, halo-phenyl, or thienyl optionally substituted by C.sub.1 -C.sub.4 alkyl or halogen, and R.sup.5 is halogen, or pharmaceutically acceptable salts thereof having a more potent and longer lasting antibacterial activities against G(+) and G(-) bacteria than known analogues, useful as antibacterial agents at an oral dose of 1-500 mg, preferably 50-100 mg per day to an adult.

Quinolinecarboxylic acids

An antibacterial 3-(alkylcarbamoyloxymethyl)-3-cephem-4-carboxylic acid or its derivatives represented by the following formula ##STR1## (wherein R is hydrogen or an amino-protecting group,

Alkylcarbamoyloxymethylcephem compounds

Growing community of inventors

Osaka, Japan

Tetsuo Okada